Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sarah Gheuens Sells 11,914 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 11,914 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the sale, the insider owned 61,271 shares of the company's stock, valued at $2,327,685.29. This trade represents a 16.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sarah Gheuens also recently made the following trade(s):

• On Tuesday, July 1st, Sarah Gheuens sold 4,091 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $34.17, for a total transaction of $139,789.47.
• On Tuesday, June 24th, Sarah Gheuens sold 2,909 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $33.54, for a total transaction of $97,567.86.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.18 during mid-day trading on Monday, reaching $39.23. The company's stock had a trading volume of 702,549 shares, compared to its average volume of 657,048. The stock has a 50-day moving average of $32.72 and a two-hundred day moving average of $32.02. The stock has a market capitalization of $2.27 billion, a P/E ratio of 3.49 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $39,000. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. CWM LLC raised its holdings in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares during the period. Sterling Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after acquiring an additional 499 shares during the last quarter.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of research reports. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank cut their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.60.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.